Literature DB >> 2297866

Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia.

P Rubba1, A Iannuzzi, A Postiglione, N Scarpato, S Montefusco, A Gnasso, G Nappi, C Cortese, M Mancini.   

Abstract

Repeat low density lipoprotein (LDL) apheresis and blood flow determinations in the forearm and leg were performed in 10 patients (age range, 13-49 years; four male, six female) with familial hypercholesterolemia (eight homozygous, two heterozygous). To perform LDL apheresis, plasma was first separated by a polysulphone hollow fiber filter; then, LDL was selectively removed from plasma by dextran sulphate cellulose beads packed in columns. Blood flows in the forearm and leg were determined at rest and during a reactive hyperemia test (peak flow). This test was performed noninvasively by a strain-gauge plethysmograph with semicontinuous registration of arterial blood flow variables before the first apheresis and 3 weeks after the last of six procedures for apheresis. Resting arterial blood flows in the forearm and leg were slightly increased after repeat LDL apheresis (p less than 0.05). Peak blood flow in the leg significantly increased (+34%, p less than 0.01). No change in peak blood flow in the forearm was observed. Systolic blood pressures were slightly but significantly reduced (p less than 0.05); forearm peripheral resistances were also reduced (p less than 0.05). Flow response was not related to LDL receptor status. Blood and plasma viscosities were determined before and 7 days after the last apheresis. Blood viscosity was significantly reduced after LDL apheresis at shear rates of 11.25-450 sec-1. Plasma viscosity did not change.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297866     DOI: 10.1161/01.cir.81.2.610

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.

Authors:  Kurt Derfler; Sabine Steiner; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2015-07-23       Impact factor: 1.704

2.  Differential impact of severe familial hypercholesterolemia on regional skeletal muscle and organ blood flows during exercise: Effects of PDE5 inhibition.

Authors:  Christian G Aragonez; Vincent J de Beer; Darla L Tharp; Douglas K Bowles; M Harold Laughlin; Daphne Merkus; Dirk J Duncker; Shawn B Bender
Journal:  Microcirculation       Date:  2019-03-26       Impact factor: 2.628

Review 3.  Clinical relevance of hyperlipidemia.

Authors:  M Mancini; P Pauciullo
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 4.  Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses.

Authors:  P M Moriarty; C A Gibson
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

5.  Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption.

Authors:  P Schulzeck; C J Olbricht; K M Koch
Journal:  Clin Investig       Date:  1992-02

6.  Correction of erythrocyte shape abnormalities in familial hypercholesterolemia after LDL-apheresis: does it influence cerebral hemodynamics?

Authors:  A Iannuzzi; G Bianciardi; F Faccenda; A Gnasso; N Scarpato; L Di Marino; G Iaccarino; C Simoes; G Sacchi; E Weber
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

7.  Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins.

Authors:  W Knisel; M Pfohl; M Müller; I Besenthal; A di Nicuolo; W Voelker; T Risler; M Eggstein
Journal:  Clin Investig       Date:  1994-09

8.  Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality.

Authors:  P Rubba; P Pauciullo; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

9.  Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.

Authors:  Akihito Tanaka; Daijo Inaguma; Yu Watanabe; Eri Ito; Naoki Kamegai; Hiroya Shimogushi; Hibiki Shinjo; Kiyomi Koike; Yasuhiro Otsuka; Asami Takeda
Journal:  Intern Med       Date:  2017-06-15       Impact factor: 1.271

10.  Role of lipid apheresis in changing times.

Authors:  Peter Schuff-Werner; Sebastian Fenger; Peter Kohlschein
Journal:  Clin Res Cardiol Suppl       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.